FGFR2 mutations are rare across histologic subtypes of ovarian cancer
Sara A Byron, Michael G Gartside, Candice L Wellens, Paul J Goodfellow, Michael J Birrer, Ian G Campbell, Pamela M Pollock
GYNECOLOGIC ONCOLOGY | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2010
OBJECTIVE: Ovarian cancer is the leading cause of death from gynecologic malignancies in the Western world. Fibroblast growth factor receptor (FGFR) signaling has been implicated to play a role in ovarian tumorigenesis. Mutational activation of one member of this receptor family, FGFR2, is a frequent event in endometrioid endometrial cancer. Given the similarities in the histologic and molecular genetics of ovarian and endometrial cancers, we hypothesized that activating FGFR2 mutations may occur in a subset of endometrioid ovarian tumors, and possibly other histotypes. METHODS: Six FGFR2 exons were sequenced in 120 primary ovarian tumors representing the major histologic subtypes. RESULTS: ..View full abstract
Awarded by Department of Defense
Awarded by American Cancer Society
We would like to thank the TGen Sequencing Core for their excellent work and Dr. John Carpten (Translational Genomics Research Institute) for providing ovarian cancer cell line DNAs. We gratefully acknowledge funding from the Department of Defense CDMRP Ovarian Cancer Research Program (W81XWH-08-1-0244, PMP), the National Health and Medical Research Council (Australia) (IGC), the Victorian Breast Cancer Research Consortium (Australia) (IGC), and the American Cancer Society (PF-07-215-01-TBE, SAB).